BiobadaBrasil: registro da sociedade e dos reumatologistas brasileiros

Abstract

I n this volume, the article Brazilian Biologic Registry: BiobadaBrasil implementation process and preliminary, the authors described the implementation of the registry "Monitoring the Brazilian Registry of Biological Therapies in Rheumatic Diseases-BiobadaBrasil" promoted by the Brazilian Society of Rheumatology (BSR), and presented data from the first ten months of the study providing this registry available to all rheumatologists and the Brazilian Society. The registry implementation was a proposal from the "First Forum of New Resources Rheumatology", held in Sao Paulo in July 2007, to create a national database of biological agents. Afterwards, a contract was signed with the BSR, PANLAR and Spanish Society of Rheumatology (SSR) in order to participate in BIOBADAMERICA in November of that year. This action was the result of the vision of President of SBR (2006-08), Fernando Neubarth, that participate in a registry already consolidated as BIOBADASER and rely on its support and advice would facilitate the implementation and consolidation of the Brazilian registry. Using a simple online platform makes this registry accessible to all study centers with internet access and all rheumatologists interested in participating. The implementation process is described in the article, with a training phase, the BiobadaBrasil I, with the system and documents adaptation from Spanish to Portuguese, staff training, and gradual implementation. In April 2009, it was officially presented in the "XX Brazilian Conference Rheumatology" in Natal, and rheumatologists were invited to participate. Throughout this period, the study was presented and discussed in all SBR events and its disclosure was made at the company website and magazine. The President of BSR (2008-10), Ieda Laurindo, actively supported the study, encouraged and guided the implementation team, and was the main responsible for implementing the study in 23 centers and including 1,037 patients until February 2010.

Seguridad de las drogas biológicas y sintéticas dirigidas utilizadas en pacientes con enfermedades reumáticas inmunomediadas. Datos del registro BIOBADASAR 3.0

“…Como se mencionó previamente, los pacientes que recibían ciclos de tratamiento que incluían DME-b/sd, presentaron mayor frecuencia y número de EA, y menor tiempo hasta el desarrollo de los mismos. Esto fue similar a lo observado en otros registros iberoamericanos, en los cuales, al igual que en nuestro caso, las infecciones, particularmente las de la vía aérea superior fueron las más frecuentemente reportadas [12][13][14][15] . Ciertos EA, incluyendo los trastornos gastrointestinales, hepatobiliares y neurológicos, fueron más prevalentes durante los ciclos de tratamientos sin DME-b/sd, situación que se observa habitualmente en la práctica diaria con el uso de agentes convencionales como el metotrexato o la leflunomida, que se incluyeron en más del 80% de los ciclos analizados.…”